High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections

BACKGROUND: Oral follow‐up therapy is problematic in moulds with reduced azole‐susceptibility, such as azole‐resistant Aspergillus fumigatus infection. Currently, only intravenous liposomal amphotericin B (L‐AmB) is advocated by guidelines for the treatment of azole‐resistant aspergillosis infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Schauwvlieghe, Alexander F. A. D., Buil, Jochem B., Verweij, Paul E., Hoek, Rogier A. S., Cornelissen, Jan J., Blijlevens, Nicole M .A., Henriet, Stefanie S. V., Rijnders, Bart J. A., Brüggemann, Roger J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003872/
https://www.ncbi.nlm.nih.gov/pubmed/31660650
http://dx.doi.org/10.1111/myc.13028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003872/
https://www.ncbi.nlm.nih.gov/pubmed/31660650
http://dx.doi.org/10.1111/myc.13028

Ejemplares similares